Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

37.40
-0.2000-0.53%
Post-market: 37.34-0.0600-0.16%19:30 EDT
Volume:1.60M
Turnover:59.67M
Market Cap:5.03B
PE:-10.74
High:38.14
Open:37.70
Low:36.86
Close:37.60
52wk High:49.70
52wk Low:10.46
Shares:134.37M
Float Shares:129.97M
Volume Ratio:0.66
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.47
PE(LYR):-18.16

Loading ...

Definium Therapeutics Shares Jump 20% Premarket After Co's Lsd-Based Drug Lowers Anxiety in Second Successful Late-Stage Study

THOMSON REUTERS
·
Sep 14

S&P 500 Futures Decline in Premarket Trading; Definium Therapeutics, Primo Brands Lead

Dow Jones
·
Sep 14

Definium Therapeutics: DT120 Odt 100 Mcg Generally Well Tolerated with Consistent Safety Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 14

Definium Therapeutics: DT120 Pre-Nda Meeting Scheduled for Q4; Nda Filing Expected H1 2027

THOMSON REUTERS
·
Sep 14

Definium Therapeutics: Phase 3 Panorama Study of DT120 Odt Met Primary & Key Secondary Endpoints in Generalized Anxiety Disorder

THOMSON REUTERS
·
Sep 14

Definium's LSD-Based Drug Lowers Anxiety in Second Successful Late-Stage Study

Reuters
·
Sep 14

Definium Therapeutics: DT120 Odt 100 Mcg Showed Placebo-Adjusted Hamilton Anxiety Rating Scale Reduction of 5.1 Points at Week 12

THOMSON REUTERS
·
Sep 14

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Sep 14

U.S. Research Roundup-ACV Auctions, Crown Castle, Lennox International

Reuters
·
Sep 14

Definium Therapeutics Issues Inducement Stock Options for 56,650 Shares to New Hires

Reuters
·
Sep 14

Definium Therapeutics to Present Phase 3 Panorama Topline Data for DT120 in Generalized Anxiety Disorder Sept. 14

Reuters
·
Sep 14

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

THOMSON REUTERS
·
Sep 14

Definium Therapeutics' Upcoming Phase 3 Data on DT120 to De-Risk Program, Back FDA Approval, RBC Says

MT Newswires Live
·
Sep 11

Definium Therapeutics Price Target Maintained with a $66.00/Share by RBC Capital

Dow Jones
·
Sep 11

Definium Therapeutics announce six poster presentations at Psych Congress

TIPRANKS
·
Sep 10

Definium Therapeutics to Present Phase 3 Topline Data for DT120 in MDD, GAD at Psych Congress 2026

Reuters
·
Sep 10

Analyst Reiterates Buy on Definium Therapeutics, Maintains $75 Price Target Following De-Risking of DT120 ODT in MDD and GAD

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Definium Rises on FDA's 'breakthrough' Tag for Depression Drug

Reuters
·
Sep 08

Definium Therapeutics Gains FDA Breakthrough for Depression Drug

TIPRANKS
·
Sep 08